Tratamiento hipometilante de los Síndromes Mielodisplásicos de la fisiopatogenia y la farmacología a la práctica clínica

Iastrebner, Marcelo; Flore, Alejandro; Benasayag, Silvia.
Hematología (B. Aires) ; 13(1): 16-28, ene.-abr. 2009. graf, tab
Artigo em Espanhol | LILACS | ID: lil-547261

Documentos relacionados

  1. Myelodysplastic syndromes, thy name is heterogeneity.
  2. The role of genetic factors in pediatric myelodysplastic syndromes with different outcomes.
  3. MYELODYSPLASTIC SYNDROME: DIAGNOSIS, TREATMENT AND PROGNOSIS (LITERATURE REVIEW).
  4. A Lower Frequency of Spliceosome Mutations Distinguishes Clonal Cytopenias of Undetermined Significance From Low-Risk Myelodysplastic Syndromes, Despite Inherent Similarities in Genomic, Laboratory, and Clinical Features.
  5. Modeling hemoglobin levels of patients chronically transfused with red blood cells.
  6. Somatic mutations show no clear association with red blood cell or human leukocyte antigen alloimmunization in de novo or therapy-related myelodysplastic syndrome.
  7. Recent Clinical and Molecular Advances for the Classification of Myelodysplastic Neoplasms.
  8. [Molecular international prognostic scoring system for myelodysplastic syndromes].
  9. Refined cytogenetic IPSS-R evaluation by the use of SNP array in a cohort of 290 MDS patients.
  10. Myeloablative versus Reduced-Intensity Hematopoietic Cell Transplantation in Myelodysplastic Syndromes: Systematic Review and Meta-analysis.